"Our study provides insight into the absolute risk for VTE among patients with AD, the relative risk for VTE among patients with AD versus other IMIDs, and the influence of confounders on VTE risk.
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer Odds ratios (ORs) from a case-control study comprising 143 CRC cases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results